Spots Global Cancer Trial Database for gastroesophageal adenocarcinoma

Every month we try and update this database with for gastroesophageal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia	NCT05954117	Esophageal Aden...	Adipose tissue ...	18 Years - 99 Years	University Hospital, Clermont-Ferrand
A Study of Personalized Neoantigen Cancer Vaccines	NCT03794128	Non Small Cell ... Colorectal Canc... Gastroesophagea... Urothelial Carc... Pancreatic Duct...	Blood collectio... Blood collectio...	18 Years -	Gritstone bio, Inc.
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma	NCT01757171	Gastric Adenoca... Gastroesophagea... Distal Esophage...	Cabazitaxel	18 Years -	Weill Medical College of Cornell University
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer	NCT03929666	HER2-expressing...	ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine	18 Years -	Jazz Pharmaceuticals
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)	NCT04021108	Gastroesophagea...	Nivolumab 240 M...	18 Years -	Weill Medical College of Cornell University
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	NCT05977322	Pancreatic Duct... Gastroesophagea... Glioblastoma Mu...	68Ga-FF58 177Lu-FF58	18 Years -	Novartis
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma	NCT06043427	Gastroesophagea...	Paclitaxel Ramucirumab Zanidatamab	18 Years -	Canadian Cancer Trials Group
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)	NCT06356311	Gastroesophagea...	Sacituzumab tir... Trifluridine-Ti... Irinotecan Paclitaxel Docetaxel	18 Years -	Merck Sharp & Dohme LLC
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	NCT05733689	Gastroesophagea...	ctDNA Blood Tes... FLOT FOLFOX FOLFIRI FOLFIRINOX PACLITAXEL with... DOCETAXEL and I... NIVOLUMAB (alon... PEMBROLIZUMAB (...	18 Years -	University of California, Irvine
Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia	NCT05954117	Esophageal Aden...	Adipose tissue ...	18 Years - 99 Years	University Hospital, Clermont-Ferrand
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	NCT05977322	Pancreatic Duct... Gastroesophagea... Glioblastoma Mu...	68Ga-FF58 177Lu-FF58	18 Years -	Novartis
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer	NCT03929666	HER2-expressing...	ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine	18 Years -	Jazz Pharmaceuticals
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma	NCT01182610	Gastroesophagea... Adenocarcinoma ... Adenocarcinomas... Adenocarcinoma ...	Panitumumab Paclitaxel Carboplatin 5FU	18 Years -	Accelerated Community Oncology Research Network
The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):	NCT05986227	Gastroesophagea...	toripalimab FOL...	18 Years - 75 Years	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers	NCT05152147	Gastric Neoplas... Gastroesophagea... Esophageal Aden...	Zanidatamab Tislelizumab Trastuzumab Capecitabine Oxaliplatin Cisplatin 5-Fluorouracil	18 Years -	Jazz Pharmaceuticals
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma	NCT01757171	Gastric Adenoca... Gastroesophagea... Distal Esophage...	Cabazitaxel	18 Years -	Weill Medical College of Cornell University
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma	NCT04164979	Gastric Adenoca... GastroEsophagea...	Cabozantinib Pembrolizumab	18 Years -	University of California, Irvine
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies	NCT01045421	Advanced Nonhem... Non-Small Cell ... Small Cell Lung... Metastatic Brea... Head and Neck S... Gastroesophagea...	MLN8237 (Aliser...	18 Years -	Millennium Pharmaceuticals, Inc.
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	NCT05733689	Gastroesophagea...	ctDNA Blood Tes... FLOT FOLFOX FOLFIRI FOLFIRINOX PACLITAXEL with... DOCETAXEL and I... NIVOLUMAB (alon... PEMBROLIZUMAB (...	18 Years -	University of California, Irvine
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer	NCT00073502	Gastroesophagea... Gastric Adenoca...	OSI-7904L	18 Years -	OSI Pharmaceuticals

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: